How should I evaluate and manage a patient presenting with markedly elevated creatine phosphokinase, transaminitis, bilirubin elevation, and acute kidney injury?

Rhabdomyolysis with Multi-Organ Injury: Immediate Diagnostic and Management Protocol

This constellation of markedly elevated CPK, transaminitis, hyperbilirubinemia, and AKI represents rhabdomyolysis with multi-organ involvement requiring immediate aggressive fluid resuscitation, nephrotoxin withdrawal, and close monitoring for complications including compartment syndrome and electrolyte derangements.

Initial Diagnostic Workup

Immediately obtain:

• CPK level (if >5,000 U/L, risk of AKI increases substantially; >15,000 U/L carries 74% risk of AKI) 1
• Serum creatinine with baseline comparison from previous 3 months if available 2
• Urine myoglobin and urinalysis (look for pigmented granular casts)
• Electrolytes focusing on potassium, calcium, phosphate
• Liver function tests (AST, ALT, total/direct bilirubin)
• Complete blood count
• Arterial blood gas if acidosis suspected
• Urine sodium and fractional excretion of sodium to differentiate prerenal from intrinsic AKI 3

Critical history elements:

• Recent medication exposures (statins, fibrates, antipsychotics, antihistamines)
• Substance use (alcohol, cocaine, amphetamines, ketamine) 4
• Recent infections or vaccinations 5
• Trauma, prolonged immobilization, or seizures
• Extreme physical exertion 6
• Heat exposure or hypothermia

Staging AKI Severity

Use KDIGO criteria 7:

• Stage 1: SCr increase ≥0.3 mg/dL within 48h OR ≥1.5-2× baseline within 7 days
• Stage 2: SCr increase >2-3× baseline
• Stage 3: SCr increase >3× baseline OR SCr ≥4.0 mg/dL with acute rise ≥0.3 mg/dL OR initiation of dialysis

Immediate Management Algorithm

For ALL Patients:

1. Aggressive Volume Resuscitation

• Initiate intravenous normal saline at 200-400 mL/hour (target urine output >200-300 mL/hour initially, then >100 mL/hour) 3
• Monitor fluid status closely to avoid pulmonary edema
• Continue until CPK declining and urine clearing

2. Medication Review and Withdrawal 8, 9, 2

• Immediately discontinue:
  • All nephrotoxic agents (NSAIDs, aminoglycosides, contrast agents)
  • Statins and other myotoxic drugs
  • ACE inhibitors/ARBs if present
  • Diuretics
  • Metformin if GFR <45 mL/min/1.73m²

3. Electrolyte Management

• Hyperkalemia: Treat if K+ >5.5 mEq/L or ECG changes present
• Hypocalcemia: Do NOT treat unless symptomatic (may worsen tissue calcium deposition)
• Hyperphosphatemia: Monitor closely
• Metabolic acidosis: Consider sodium bicarbonate if pH <7.1 9

Stage-Specific Management:

Stage 1 AKI:

• Continue aggressive hydration
• Monitor CPK, creatinine, electrolytes every 12-24 hours
• Reassess volume status frequently

Stage 2-3 AKI:

• Consider ICU admission for closer monitoring
• Monitor for compartment syndrome (measure compartment pressures if limb swelling/pain present)
• Prepare for potential renal replacement therapy

Indications for Dialysis

Initiate renal replacement therapy for 3:

• Refractory hyperkalemia (K+ >6.5 mEq/L despite medical management)
• Volume overload with pulmonary edema unresponsive to diuretics
• Severe metabolic acidosis (pH <7.1) refractory to bicarbonate
• Uremic complications (encephalopathy, pericarditis)
• Severe azotemia (BUN >100 mg/dL with symptoms)

Note: Patients with CPK >300,000 U/L may require dialysis despite aggressive hydration 4, but full renal recovery is possible even with very high CPK levels and temporary dialysis dependence 4.

Hepatic Involvement Considerations

The transaminitis and hyperbilirubinemia likely represent:

1. Direct muscle enzyme release (AST from muscle breakdown)
2. Hepatic hypoperfusion from volume depletion
3. Possible drug-induced hepatotoxicity if medication-related

Do NOT use infliximab if considering immunosuppression, as it is contraindicated in hepatic injury 10.

Critical Pitfalls to Avoid

1. Underestimating fluid requirements: Rhabdomyolysis requires massive volume replacement (often 10+ liters in first 24 hours)
2. Treating asymptomatic hypocalcemia: May precipitate tissue calcification
3. Continuing nephrotoxic medications: Even "essential" medications must be stopped temporarily 8, 9
4. Assuming drug-induced myopathy alone: Consider autoimmune myositis if weakness persists despite drug withdrawal, especially in elderly patients on chronic statins 11. Check myositis-specific antibodies (anti-Mi-2, anti-Jo-1, anti-PL-7, anti-HMG-CoA reductase)
5. Missing delayed presentations: AKI from rhabdomyolysis can present weeks after the initial muscle injury when CPK has normalized 5

Monitoring Parameters

Daily until improving:

• CPK (expect 30-50% decline daily with adequate hydration)
• Serum creatinine
• Electrolytes (K+, Ca2+, PO4-)
• Urine output
• Volume status assessment

Recovery indicators:

• CPK declining toward normal (<1,000 U/L)
• Creatinine stabilizing or improving
• Urine clearing (from tea-colored to normal)
• Urine output maintained >0.5 mL/kg/hour

Special Consideration: Autoimmune Myositis

If weakness persists beyond 48-72 hours despite drug withdrawal and adequate hydration, obtain myositis antibody panel and consider muscle biopsy 11. Autoimmune myositis may coexist with drug-induced myopathy and requires high-dose corticosteroids (methylprednisolone 1-2 mg/kg/day) for disease control 11.